Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05187338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 30, 2024 to Oct 30, 2029
    • Study completion date: Oct 30, 2025 to Oct 30, 2035
    v4
  2. Primary completion date: Oct 30, 2023 to Oct 30, 2024v3
  3. Primary endpoints revised (4)
    • Study arms: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).
Trial Details
NCT Number NCT05187338
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer +3 more
Related terms Breast Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Uterine Cervical Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov